Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - therapeutics+%3e+oncology
138
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
UCHL1 Inhibitors, Modifications, and Uses Thereof (UCLA Case No. 2026-123)
UCLA researchers in the Department of Molecular & Medical Pharmacology and have developed novel, highly potent small-molecule inhibitors of UCHL1 that selectively suppress tumor growth and metastasis in aggressive cancers with favorable in vivo safety profiles. BACKGROUND: Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) is a dual-function enzyme...
Published: 3/11/2026
|
Inventor(s):
Tanya Stoyanova
,
Michael Jung
Keywords(s):
Category(s):
Diagnostic Markers > Cancer
,
Therapeutics > Oncology
,
Therapeutics > CNS and Neurology
,
Therapeutics > Oncology
> Oncology (Small Molecules)
Engineered Gamma Delta T-Cells and Methods of Making and Using Thereof (UCLA Case No. 2020-913)
UCLA researchers in the Department of Molecular Immunology & Molecular Genetics have developed gamma delta (gd) T cell receptor gene-modified immune cells derived from stem and progenitor cells that enable scalable, off-the-shelf allogeneic cell therapies with broad therapeutic potential. BACKGROUND: Cell-based immunotherapies have demonstrated...
Published: 3/4/2026
|
Inventor(s):
Lili Yang
,
Derek Lee
,
Tyler Halladay
Keywords(s):
Category(s):
Diagnostic Markers > Immunology
,
Diagnostic Markers > Cancer
,
Life Science Research Tools > Cell Lines
,
Therapeutics > Oncology
,
Therapeutics > CNS and Neurology
,
Therapeutics > Hematology
,
Therapeutics > Autoimmune
,
Therapeutics > Gene Therapy And Editing
,
Therapeutics > Stem Cells And Regenerative Medicine
,
Therapeutics > Infectious Diseases
Microbial Regulation of Immune Tolerance and Risk for Cancer (UCLA Case No. 2026-153)
Details available soon. Please contact UCLA Technology Development Group if you have any questions or would like more information in the meantime.
Published: 3/4/2026
|
Inventor(s):
Elaine Hsiao
Keywords(s):
Category(s):
Therapeutics > Oncology
,
Therapeutics > Immunology And Immunotherapy
Transient Transcription Factor Reprogramming to Rejuvenate Exhausted Tumor-Specific T Cells Into Stem-Like Memory T Cells (UCLA Case No. 2024-240)
Details available soon. Please contact UCLA Technology Development Group if you have any questions or would like more information in the meantime.
Published: 3/9/2026
|
Inventor(s):
Tyler McCaw
Keywords(s):
Category(s):
Therapeutics > Oncology
,
Therapeutics > Immunology And Immunotherapy
Compositions and Methods to Modulate MAVS-Mediated Immunity (UCLA Case No. 2026-096)
UCLA researchers in the Department of Microbiology, Immunology, and Molecular Genetics have developed methods to target TOM70, a mitochondrial outer membrane protein, to selectively modulate innate immune signaling and control pathological or protective immune responses across a range of clinical conditions. BACKGROUND: Innate immune detection of viral...
Published: 2/18/2026
|
Inventor(s):
Lena Pernas
Keywords(s):
Category(s):
Diagnostic Markers > Targets And Assays
,
Diagnostic Markers > Immunology
,
Diagnostic Markers > Cancer
,
Platforms > Diagnostic Platform Technologies
,
Therapeutics > Oncology
,
Therapeutics > Infectious Diseases
,
Therapeutics > Immunology And Immunotherapy
,
Therapeutics > Inflammation And Inflammatory Diseases
,
Therapeutics > Autoimmune
,
Therapeutics > Vaccines
The Use of Voltage Sensitive Mitochondrial Uncouplers as Selective Anti-Cancer Drugs (UCLA Case No. 2022-327)
UCLA researchers from the Department of Medicine have identified an anti-cancer drug that targets mitochondrial membrane potential to selectively kill tumor cells, showing efficacy for traditionally treatment-resistant lung cancers. BACKGROUND: Non-small cell lung cancer (NSCLC) is a devastating disease that will claim the lives of approximately 125,000...
Published: 2/17/2026
|
Inventor(s):
David Shackelford
Keywords(s):
Category(s):
Therapeutics > Respiratory And Pulmonary
,
Therapeutics > Oncology
Regulated Gene Expression During Differentiation of Mature T Cells (UCLA Case No. 2022-147)
UCLA researchers from the Department of Pathology & Laboratory Medicine have developed a process to genetically modify stem cells to express transgenes in a regulated, stage-specific manner, avoiding the negative consequences of transgene expression during T cell development. Contact UCLA Technology Development Group for more information.
Published: 1/27/2026
|
Inventor(s):
Gay Crooks
,
Donald Kohn
Keywords(s):
Category(s):
Therapeutics > Gene Therapy And Editing
,
Therapeutics > Stem Cells And Regenerative Medicine
,
Therapeutics > Oncology
,
Therapeutics > Immunology And Immunotherapy
,
Therapeutics > Inflammation And Inflammatory Diseases
Enhancing T Cell Production in Vitro From Stem and Progenitor Cells (UCLA Case No. 2022-257)
UCLA researchers from the Department of Pathology and Laboratory Medicine have developed an innovative differentiation method to increase T cell production for T cell immunotherapy. Contact UCLA Technology Development Group for more information.
Published: 1/27/2026
|
Inventor(s):
Gay Crooks
,
Christopher Seet
Keywords(s):
Category(s):
Therapeutics > Oncology
,
Therapeutics > Immunology And Immunotherapy
Peri-Operative Cancer Therapy to Preserve Anti-Tumor Immune Surveillance (UCLA Case No. 2025-257)
UCLA Researchers from the Department of Surgery have developed a novel approach to preserve anti-tumor immunity in the peri-operative period through modulation of clinically relevant molecular and cellular targets. BACKGROUND: Surgical resection with curative intent is a mainstay of treatment for many solid tumors. However, even when the tumor is macroscopically...
Published: 2/4/2026
|
Inventor(s):
Tyler McCaw
,
Joseph Crompton
Keywords(s):
Category(s):
Therapeutics > Oncology
,
Therapeutics > Immunology And Immunotherapy
Generation of Therapeutic Human Anti-Trop-2 Extracellular Domain Antibodies (UCLA Case No. 2026-026)
UCLA researchers from the Department of Molecular and Medical Pharmacology and the Department of Microbiology, Immunology and Molecular Genetics have developed a panel of human antibodies and chimeric antigen receptors targeting Trop-2, providing diagnostic and therapeutic resources for targeting Trop2-driven cancer. BACKGROUND: Trophoblast cell surface...
Published: 12/23/2025
|
Inventor(s):
Tanya Stoyanova
,
Owen Witte
Keywords(s):
Category(s):
Diagnostic Markers > Cancer
,
Diagnostic Markers > Targets And Assays
,
Life Science Research Tools > Antibodies
,
Therapeutics > Oncology
,
Therapeutics > Immunology And Immunotherapy
1
2
3
4
5
6
7
8
9
10
...